10037415 - GAU: 1636

Receipt date: 09/24/2009 Page 1 of 1

(Use several sheets if necessary)	timore
INFORMATION DISCLOSURE STATEMENTS (Use several sheets if necessary) Art Unit 1636 Examiner Name C. Hibber 175723-	
75.72.3 – 1	rt -
75.72.3 – 1	rt
75.72.3 –	
SEP Z Attorney Docket No. ZB/JPW/G	JG/CS
NON PATENT LITER DOCUMENTS	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of th Initials* No. look, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publish and/or country where published.	
Order issued August 21, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lizand Company, U.S. Court of Appeals for the Federal Circu Docket No. 2008-1248; and	ly
Decision issued June 1, 2009 in the concurrent litigation captioned Amgen, Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023.	n
EXAMINER /Catherine Hibbert/ DATE CONSIDERED 02/09/2010	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.

Serial No.: 10/037,415 Filed: January 4, 2002

Exhibit A